PBandB

Executive Summary

PBandB is a Swiss medical aesthetics company founded in 2013, pioneering a novel technology that uses plant-derived lipids to stimulate a patient's own fat cells for natural, long-lasting volume restoration in facial and body tissues. The company's approach aims to address the limitations of current injectable fillers by leveraging the body's own regenerative mechanisms, potentially offering more durable and biocompatible aesthetic outcomes. Currently in clinical development, PBandB's products are limited to investigational use, but the technology holds promise for the rapidly growing medical aesthetics market. The company is privately held and based in Zurich, Switzerland. With an innovative platform that could disrupt traditional fat grafting and synthetic fillers, PBandB is positioned to address significant unmet needs in non-surgical body contouring and facial rejuvenation. The company's success will depend on demonstrating safety and efficacy in ongoing and planned clinical trials, securing regulatory approvals, and establishing manufacturing and commercial partnerships. As a private company, PBandB's valuation and funding history are not publicly disclosed, but its unique plant-derived approach differentiates it from competitors using hyaluronic acid or synthetic polymers. The aesthetic market's demand for natural-looking, longer-lasting results provides a favorable backdrop for PBandB's technology. Key risks include clinical trial outcomes, regulatory hurdles, and competition from established players and emerging technologies.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Clinical Trial Results for Facial Fat Remodeling60% success
• Q2 2027Regulatory Submission for CE Mark or FDA Breakthrough Designation50% success
• Q3 2026Series B or C Funding Round Announcement70% success